Form D · Other
Neurogene Inc.
New York, NY · CIK 0001768250
Offering snapshot reported Dec 29, 2020 · SEC filing
- Reported sold
- $69M Offering amount: $115M
- Investors reported
- 32 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 15, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 29, 2020 | Initial | $68,999,980 | No comparison | 32 | SEC filing |
| Feb 25, 2019 | Initial | $37,500,001 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-384658
Source: Form D, filed Dec 29, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Baffi | Director |
| Stephen Biggar | Director |
| Christine Mikail Cvijic | Executive |
| Cory Freedland | Director |
| Rachel Mc Minn | Director, Executive |
| Srdjan Stankovic | Director |
| Caroline Stout | Director |
Issuer details
Industry: Other (See others in industry)
Address:
535 W. 24th St Fl 5
New York, NY, 10011
New York, NY, 10011